Evidence map›Paper›PMID 32769621›Full record

ArticleCritical care medicine2020

Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.

Mihir R Atreya, Brynne E Whitacre, Natalie Z Cvijanovich, Michael T Bigham, Neal J Thomas, Adam J Schwarz, Scott L Weiss, Julie C Fitzgerald, Geoffrey L Allen, Riad Lutfi and 4 more

Open access · greenAbstract read
In one paragraph

Article in Critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Observational
  7. Article
  8. Review
  9. Review
  10. The Multifaceted Biology of PCSK9.Endocrine reviews · 2022
    Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Mihir R AtreyaDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, OH.
Brynne E WhitacreDepartment of Pathobiology and Laboratory Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH.
Natalie Z CvijanovichUCSF Benioff Children's Hospital Oakland, Oakland, CA.
Michael T BighamAkron Children's Hospital, Akron, OH.
Neal J ThomasPenn State Hershey Children's Hospital, Hershey, PA.
Adam J SchwarzChildren's Hospital of Orange County, Orange, CA.
Scott L WeissThe Children's Hospital of Philadelphia, Philadelphia, PA.
Julie C FitzgeraldThe Children's Hospital of Philadelphia, Philadelphia, PA.
Geoffrey L AllenChildren's Mercy Hospital, Kansas City, MO.
Riad LutfiRiley Hospital for Children, Indianapolis, IN.
Jeffrey E NowakChildren's Hospital and Clinics of Minnesota, Minneapolis, MN.
Michael W QuasneyCS Mott Children's Hospital at the University of Michigan, Ann Arbor, MI.
Amy S ShahDivision of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Hector R WongDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, OH.
Children's Hospital of Philadelphia · USUniversity of Cincinnati Medical Center · USAkron Children's Hospital · USChildren's Hospital of Orange County · USChildren's Mercy Hospital · USChildren's Minnesota · USCincinnati Children's Hospital Medical Center · USPenn State Milton S. Hershey Medical Center · USRiley Hospital for Children · USUCSF Benioff Children's Hospital · US

Funding

Supplement for MIRA award_Wong_2021R35GM126943 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI ALDER, MATTHEW N · 2018 to 2022
$2.7M
Mitochondrial Dysfunction in Pediatric SepsisK23GM110496 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI WEISS, SCOTT L · 2015 to 2018
$723k
PCSK9 and Pediatric Sepsis-Related MODSR21HD092896 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI WONG, HECTOR R. · 2018 to 2019
$437k
NICHD NIH HHS R21 HD092896NIGMS NIH HHS K23 GM110496NIGMS NIH HHS R35 GM126943
6 · The paper itself

Abstract

objectivesProprotein convertase subtilisin/kexin type 9 is a central regulator of lipid metabolism and has been implicated in regulating the host response to sepsis. Proprotein convertase subtilisin/kexin type 9 loss-of-function is associated with improved sepsis outcomes in the adult host through increased hepatic bacterial clearance. Thus, there is interest in leveraging proprotein convertase subtilisin/kexin type 9 inhibitors as a therapeutic strategy in adults with sepsis. We sought to validate this association in children with septic shock and in a juvenile murine model of sepsis.

designProspectively enrolled cohort of children with septic shock; experimental mice.

settingSeventeen participating institutions; research laboratory. PATIENTS AND SUBJECTS: Five-hundred twenty-two children with septic shock; juvenile (14 d old) and adult (10-14 wk) mice with constitutive proprotein convertase subtilisin/kexin type 9 null and wildtype control mice (C57BL/6).

interventionsProprotein convertase subtilisin/kexin type 9 single-nucleotide polymorphisms, serum proprotein convertase subtilisin/kexin type 9, and lipid profiles in patients. Cecal slurry murine model of sepsis; survival studies in juvenile and adult mice, assessment of lipoprotein fractions, bacterial burden, and inflammation in juvenile mice. MEASUREMENTS AND MAIN

resultsPCSK9 loss-of-function genetic variants were independently associated with increased odds of complicated course and mortality in children with septic shock. PCSK9, low-density lipoprotein, and high-density lipoprotein concentrations were lower among patients with complicated course relative to those without. PCSK9 concentrations negatively correlated with proinflammatory cytokine interleukin-8. Proprotein convertase subtilisin/kexin type 9 loss-of-function decreased survival in juvenile mice, but increased survival in adult mice with sepsis. PCSK9 loss-of-function resulted in low lipoproteins and decreased hepatic bacterial burden in juvenile mice.

conclusionsIn contrast to the adult host, proprotein convertase subtilisin/kexin type 9 loss-of-function is detrimental to the juvenile host with septic shock. PCSK9 loss-of-function, in the context of low lipoproteins, may result in reduced hepatic bacterial clearance in the juvenile host with septic shock. Our data indicate that children should be excluded in sepsis clinical trials involving proprotein convertase subtilisin/kexin type 9 inhibitors.

Indexed as

AnimalsBiomarkersChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleHumansInfantInflammation MediatorsIntensive Care Units, PediatricLipidsLogistic ModelsMaleMiceMice, Inbred C57BLOrgan Dysfunction ScoresBiomarkersInflammation MediatorsLipidsPCSK9 protein, humanProprotein Convertase 9

Identifiers

PMID32769621
PMCPMC8477606
OpenAlexW3047664698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.